Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
This year marks the first full season that Seqirus' portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of ...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Centers for Disease Control...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the company's manufacturing facility...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting...
The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza...
Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug...
Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the Biomedical Advanced Research and...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced plans to accelerate the development of its...
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), presented findings from a new observational safety study...
Seqirus offers a differentiated portfolio of influenza vaccines, including FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first and only cell-based ...
Seqirus, a global leader in influenza prevention and a division of CSL Limited (ASX: CSL), today announced that the company co-authored the first...
Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company's cell-based quadrivalent...
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, ...
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based...
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX®...
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the European Scientific Working Group on Influenza ...
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced the presentation of new data at the European...
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and ...
Seqirus, a global leader in influenza prevention, today presented absolute efficacy data on the company's cell-based quadrivalent influenza vaccine...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.